# 7 Spending functions

The gsDesign web interface sets interim boundaries using spending functions. The capabilities allow a great deal of flexibility. We discuss these capabilities and the tradeoffs of different approaches.

- Parameter-free spending functions
- One-parameter spending functions
- Two- and three-parameter spending functions
- Piecewise-linear spending functions

## 7.1 Overview and definition

Spending functions allow flexibility when the timing or number of interim analyses changes during the course of a trial. This will be demonstrated further in Chapter 8. Here we discuss how to choose spending functions at the time of design. We begin with spending functions without parameters, one of which is frequently used. This is followed by one-parameter spending functions that provide additional flexibility and discuss when that flexibility may be desirable. The ultimate flexibility if supplied by piecewise-linear spending functions, which are explained next. We end with 2- and 3-parameter spending functions that also provide increased flexibility over single-parameter spending functions.

The CAPTURE trial (The CAPTURE Investigators, 1997) was one of the first trials designed by one of the co-authors (KA) of this book. The statistician for the data monitoring committee was Jan Tijssen from the Academic Medical Center in Amsterdam. Professor Tijssen’s thoughts influenced the CAPTURE trial design as well as the thoughts behind several subsequent trials. The basic philosophy suggested is:

- Set the timing of interim analyses so that the analyses are relevant. That is, do they come at a time that is distinctly different than the final analysis.
- Set the efficacy bounds so that they are stringent both from a Type I error perspective and if the trial is stopped, the treatment effect observed is likely to be clinically significant.
- Set futility bounds so that a trial is not stopped too soon (Type II error), but also see if the approximate treatment effect at the futility bound is poor enough that it would not encourage continuing the trial. Also, the timing must be relevant in that substantial time or savings (in terms of patient enrollment and/or costs) is achieved.

These thoughts are expressed more fully in an article by
Anderson and Clark^{17} and we try to reflect them also here.
Since the software specifically estimates the number of patients
enrolled at analysis cutoff dates corresponding to achieving a specified
number of events for time-to-event endpoints, we focus on such designs
here. Note that if there is a substantial gap between the data cutoff
and when a decision may be made based on an interim analysis, then
enrollment when the trial is actually stopped may be substantially
larger than stated here.
This should be taken into account when considering a design.

In the following, we continue the example from Chapter 2 where we began with a fixed design sample size of 100 and powered the trial to detect a treatment effect of \(\delta = 5\).

Spending functions are non-decreasing (usually increasing and
continuous) functions that are used to select the probability of
crossing each interim boundary having not previously crossed a bound. A
Type I error spending functions \(f(t)\) is defined
for \(0 \leq t\) and with \(f(t) = \alpha\) for \(t \geq 1\).
Analogously, a Type II error spending function
\(g(t)\) is defined for \(0 \leq t\) and has \(g(t) = \beta\), the Type II error
(one minus the power) for \(t \geq 1\). For normal or binomial endpoints,
\(t\) represents the proportion of the final planned sample size included at the
time of an analysis. For a time-to-event endpoint, \(t\) represents
the proportion of the final planned number of events included at
the time of an analysis. For information-based design, \(t\) represents
the proportion of the final planned **statistical information**
at the time of an analysis. We let \(t_i\) represent the proportion of
total sample size at analysis \(i\) where \(i = 1, 2, 3\) in this case. The
actual probability of first crossing an efficacy bound at analysis \(i\)
under the null hypothesis is \(f (t_i) - f (t_{i-1})\) where \(t_0 = 0\).
The probability of first crossing a futility bound at analysis \(i\) is
\(g(t_i) - g(t_{i-1})\). For those interested in more mathematical detail,
the books by Jennison and Turnbull^{18} or Michael A Proschan, KK Gordon Lan, and Janet Turk Wittes^{19} provide nice introductions.

The web interface provides a spending function plot. Below you see an example using O’Brien-Fleming-like spending function for efficacy (solid line) and Pocock-like spending function for futility (dashed line) as described in the next two sections. Recall that we have been planning analyses after 35% and 70% of observations are available. For the 35% analysis (t = 0.35), you can see that essentially no \(\alpha\)-spending is planned (solid line), while for the 70% analysis, approximately 30% of the final spending is planned. A much larger proportion of \(\beta\)-spending is early in the trial. You can see the actual spending at analyses in the “Text” tab as shown below.

The \(\alpha\)-spend at each analysis, \(f(t_i) - f (t_{i-1})\), is in the “Spend++” column. The \(\beta\)-spend at each analysis, \(g(t_i) - g(t_{i-1})\), is in the “Spend+” column. You can see that the total \(\alpha\)-spend is equal to the total Type I error of 0.025 and that the total \(\beta\)-spend is equal to the total Type II error of 0.10, or one minus the power. The “Spend+” footnote indicates that \(\beta\)-spending, the probability of crossing a futility bound and stopping under the alternate hypothesis \(H_1\), is in this column; the footnote also provides the spending function used. The “Spend++” footnote indicates that \(\alpha\)-spending is in this column and indicates the spending function used.

Next we examine the lower part of the output in the “Text” tab. The \(\alpha\)-spending in this table is actually lower than that provided by \(f(t)\) for asymmetric designs with non-binding futility bounds; in this case \(\alpha\)-spending is computed as if crossing the futility bound is ignored. In this table however, probabilities are all computed assuming the trial stops the first time a boundary is crossed. Note that the “Theta” column displays in the lower table is the standardized effect size which is 0 under the null hypothesis and 0.3245 under the alternative hypothesis for this example; further definition of the standardized effect size is beyond the scope of this book. The top row in the “Upper boundary” table indicates the Type I error assuming the trial actually stops and cannot subsequently cross an efficacy bound if a futility bound is crossed; the total Type I error indicated here is 0.0197, less than the 0.025 Type I error that assumes the trial does not stop if the lower bound is crossed. Depending on the spending functions used, especially the \(\beta\)-spending function \(g()\), this can be closer to or further from the design Type I error. Power is in the second row of this table; you can see the probability of first crossing an efficacy bound under the alternate hypothesis at each analysis as well as the total power of 0.90. The lower table shows probabilities of crossing the lower bounds under the null (first row) and alternate (second row) hypotheses.

By switching the boundary type to “Asymmetric, binding” in the “Boundaries” input tab, we get \(\alpha\)-spending in the lower table equal to that in the upper table since the spending computations assume crossing any boundary stops the trial and no subsequent bound can be crossed:

## 7.2 Parameter-free spending functions

Gordon Lan and DeMets^{20} were the first to propose spending functions
to control Type I error in group sequential trials. Their
methods allowed more flexibility in setting the timing of analyses
than previous design methods using boundary families. As
specific examples, they proposed spending functions to approximate
bounds created using boundary families that were published
by Pocock^{21} and O’Brien and Fleming^{22}.
These spending functions are selected under the “Boundaries”
tab using the “No parameters” option as seen in the following
figure. The two options under “Spending function” in this case
are “O’Brien-Fleming-like” and “Pocock-like.”

### 7.2.1 Pocock-like bounds

Pocock^{23} efficacy bounds provide equal \(Z\)-values at each
efficacy analysis. The “Pocock-like” spending function of
Gordon Lan and DeMets^{24} approximates this bound as follows for the
following design that is otherwise like that in Chapter 4 where a
fixed design sample size of 100 was required and the treatment
effect that the trial was powered for was \(\delta = 5\).

You can see that the upper bounds are approximately, but not exactly equal. Generally Pocock-like bounds are not used as they increase the maximum sample size substantially over the corresponding fixed design with the same Type I error and power (a 37% increase in sample size in this case) and the treatment effect required to cross an interim efficacy bound can be substantially smaller than that for which the trial is powered. In this case, a treatment effect of \(\hat{\delta} = 3.6\) is estimated to be required to cross the second interim efficacy bound, while the trial was powered to detect a larger treatment effect of \(\delta = 5\). You can see this treatment effect estimate either by selecting the “Treatment effect” plot (next figure) or by looking under the “Tabular” output tab. Recall that this design is powered to detect \(\delta = 5\). Note that at the second interim we estimate that \(\hat{\delta} = 3.61 < 5\) is required to cross the efficacy bound. Since regulators generally advise against early stopping for efficacy other than for extreme results, this may be a consideration in choosing an even more conservative bound. The treatment effect required to cross the futility bound at the second interim may be undesirably close to what is required at the final analysis to stop the trial.

Pocock-like bounds may be useful in cases such as 1) a trial for
a treatment that is already proven for a related condition or 2)
an experiment where you just need a statistically significant finding
and hope to stop early to establish a proof-of-concept.
A Bayesian design with efficacy boundaries similar to a Pocock bound where used for a COVID vaccine trial (Fernando P Polack et al.^{25}), presumably as an effort to accelerate early boundary crossing.

### 7.2.2 O’Brien-Fleming-like bounds

The O’Brien-Fleming-like spending function often seems to be suggested by regulators to produce bounds that are acceptable to them. Interim bounds are more strict for O’Brien-Fleming designs than for Pocock designs. They also have the advantage of not substantially increasing the sample size over a fixed design.

You can see that the \(Z\)-values required to cross the bounds are more extreme for the interim analyses and less extreme for the final analysis than for design with Pocock-like spending functions. The sample size is only increased to 107 from the fixed design requirement of 100 compared to a requirement of 137 using Pocock-like spending functions. Note that if you use an O’Brien-Fleming-like spending function for efficacy and Pocock-like spending function for futility as in the previous section, an intermediate sample size of 124 is required for the group sequential design.

## 7.3 One-parameter spending functions

We present three families of spending functions here which are defined by a single parameter. Each of these can be used in a similar fashion.

### 7.3.1 Hwang-Shih-DeCani spending functions

Hwang-Shih-DeCani spending functions are defined with a parameter usually denoted by \(\gamma\); in the web interface, \(\gamma\) can range from -20 to 10. The next figure, drawn in R with the gsDesign and ggplot2 packages shows the types of shapes that are included in this family. All of the families in this section have a very similar look, with curves ranging from highly convex to highly concave and relative linearity in the middle. You can see that each of the spending function families has curves similar to the Pocock-like and O’Brien-Fleming-like spending function. The Hwang-Shih-DeCani and power spending functions are presumably widely used due to the flexibility they provide.

Among the one-parameter families, you can see that the defaults are Hwang-Shih-DeCani spending functions with \(\gamma = -8\) for the efficacy bound and \(\gamma = -2\) for the futility bound. Thus, we will discuss these selections in some detail here. Since the tabular output has all of the information we need, we present that.

Note that the interim efficacy bounds require very small nominal \(p\)-values for the bounds to be crossed and that the treatment effect (delta at bound) estimated to be needed to cross each bound is bigger than the \(\delta = 0.5\) that we powered the trial for. There is also minimal increase over the sample size of 100 required for the fixed design. On the other hand, the futility bound at the first interim analysis does not even require a positive trend to continue the trial (\(\hat{\delta} = -0.43\)) and thus might be termed a ‘disaster’ check. This is probably fine for many trials, especially for a treatment that has been previously proven in a related disease condition. The family is indexed by a parameter normally denoted by \(\gamma\) and has the formula

\[ f(t) = \alpha \frac{1 - \exp (-\gamma t)}{1 - \exp (-\gamma)}. \]

### 7.3.2 Power spending functions

Power spending functions are commonly presented in Jennison and Turnbull^{26}.
You can see below that the shapes provided are very much like those
from the Hwang-Shih-DeCani family.

The parameter indexing the power spending function family is denoted by \(\rho > 0\) and the spending function formula is \(f(t) = \alpha \times t^{\rho}\). This formula makes it particularly easy to set the spending value for a single interim analysis. Assume we wish to set \(f(t_1) = x\alpha\) where \(0 < t_1\), \(x < 1\), then we have \(\rho = \log(x) / \log(t_1)\).

### 7.3.3 Exponential spending functions

Exponential spending functions take the form \(f(t) = \alpha^{t^{-\nu}}\) where \(0 < \nu \leq 1.5\) in the web interface. As you can see, the shapes are similar to those provided by Hwang-Shih-DeCani and power spending function families.

One thing we have noted is that with \(\nu \approx 0.75\), this can provide a better approximation to actual O’Brien-Fleming bounds than other spending functions. Formally, an O’Brien-Fleming bound takes the form \(c/\sqrt{t_i}\) where \(c\) is a constant depending on \(\alpha\) and the values \(t_i\) representing the fractions of information where analyses are planned. We look at \(B_i = Z_i \times \sqrt{t_i}\) boundaries for \(\nu = 0.75\) for the design we have been using and see that the efficacy bounds are nearly constant, corresponding very closely to O’Brien-Fleming bounds:

## 7.4 Piecewise-linear spending functions

Piecewise-linear spending functions allow you to completely customize the amount of \(\alpha\)-spending and \(\beta\)-spending at each planned analysis as shown in the following graph.

This was produced by setting parameters as follows in the “Boundaries” tab in the input panel:

These tables select values of \(t\), the proportion of sample size at
which we wish to define the piecewise-linear spending function,
in the left-hand column. In this case, we have used the values
of t where analyses are planned. In the right-hand column we
specify the proportion of the total spending planned the corresponding
value of \(t\); *i.e.*, \(f(t) / \alpha\) for \(\alpha\)-spending and
\(g(t) / \beta\) for \(\beta\)-spending.
We can see that we want to spend half of the Type II
error at the first interim and only 5% more at the second interim.
The actual spending function values thus require multiplying by
\(\alpha\) and \(\beta\), respectively. For \(\alpha\)-spending this means
0.004 \(\times\) 0.025 = 0.0001 at interim 1 and an additional 0.0001 at the
second interim.

These selections result in the summary of the bounds from the
“Tabular” output that is shown in the next column. We note first
that the nominal \(p\)-values for efficacy at each interim are
0.0001, which correspond to so-called **Haybittle-Peto bounds**.
We can see that the approximate treatment effect required to
cross an interim efficacy bound is bigger than the \(\delta = 5\) that the
trial is powered for. The futility bound at the first interim gives us
a 65% chance of stopping for futility under the null hypothesis
(last column, P(Cross if delta=0)). The approximate treatment
effect corresponding to crossing this bound is a little less than
1, so at least a positive trend is required to pass the futility
analysis; for the second interim where little additional \(\beta\)-spending
occurs (little chance to cross the futility bound when
the true \(\delta = 5\)), there is still approximately a treatment effect of
\(\hat{\delta} = 1\) required to exceed the futility bound. These are the types
of evaluations you may wish to consider in selecting bounds.

Note that you may wish to use \(t\)-values that exceed the actual planned timing in case actual enrollment exceeds planned at an interim analysis; we will come back to this in Chapter 8.

## 7.5 2- and 3-parameter spending functions

Two- and three-parameter spending functions provide an alternate way for customizing spending at two points in time. The curves are smoother than piecewise-linear, but can only fit spending values at two points with the partial exception of the 3-parameter \(t\)-distribution spending function. The interface looks a little different, but is used largely like the piecewise-linear interface as seen in the next column in that we input relative timing and relative spending for both \(\alpha\)- and \(\beta\)-spending. We have used the same values here are for the piecewise-linear spending functions in the previous section. The \(\beta\)-spending function in this case is the 2-parameter Cauchy spending function, while the \(\alpha\)-spending function is the 3-parameter \(t\)-distribution spending function, in this case with 1.5 degrees of freedom. The rationale for these functions is to provide additional smooth curve options for spending functions beyond the shapes provided by one-parameter spending functions. The smoothing may be preferred when adjusting timing of analyses as in the references chapter.

The plot for these two spending functions is shown below. The Cauchy was chosen for the \(\beta\)-spending function since it was smoother than the other 2-parameter options shown in the next column. Note that the \(\alpha\)-spending function implies that any analysis after about 90% of the planned information uses essentially all Type I error that has not previously been spent. Try the different 2-parameter functions for each spending function as well as the 3-parameter \(t\)-distribution using different values for degrees of freedom. All of these functions run through the same values at 0.35 and 0.7 as specified on the previous page. Also try different values for relative spending to see how the spending function curve shapes change.

These spending functions are all of the form

\[f(t) = F(b \times (F^{-1} (t) - a)))\]

where \(a\) is any real number and \(b > 0\) and \(F(t)\) is a cumulative
distribution function defined for all real values. Thus, the name
of each of these spending function families corresponds to the
distribution function \(F(t)\) that is used in the above formula. It is
straightforward but beyond the scope of the presentation here
to show how to fit these functions through two specified points;
see Anderson and Clark^{27}.